Arcturus Therapeutics Holdings Inc (ARCT)
22.03
+0.26
(+1.19%)
USD |
NASDAQ |
Sep 27, 16:00
21.55
-0.48
(-2.18%)
After-Hours: 20:00
Arcturus Therapeutics Holdings SG&A Expense (Annual): 52.87M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 52.87M |
| December 31, 2022 | 46.07M |
| December 31, 2021 | 41.45M |
| December 31, 2020 | 23.22M |
| December 31, 2019 | 12.66M |
| December 31, 2018 | 20.58M |
| December 31, 2017 | 7.572M |
| Date | Value |
|---|---|
| December 31, 2016 | 3.448M |
| December 31, 2015 | 2.574M |
| December 31, 2014 | 5.839M |
| December 31, 2013 | 3.224M |
| December 31, 2012 | 0.683M |
| December 31, 2011 | 2.084M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
12.66M
Minimum
2019
52.87M
Maximum
2023
35.25M
Average
41.45M
Median
2021
SG&A Expense (Annual) Benchmarks
| Fulcrum Therapeutics Inc | 41.67M |
| Bioventus Inc | 303.88M |
| Semler Scientific Inc | 32.44M |
| Liquidia Corp | 44.74M |
| AIM ImmunoTech Inc | 21.14M |